These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 34943877)

  • 1. Co-Expression of Nogo-A in Dopaminergic Neurons of the Human Substantia Nigra Pars Compacta Is Reduced in Parkinson's Disease.
    Eyer GC; Di Santo S; Hewer E; Andereggen L; Seiler S; Widmer HR
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
    Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
    Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
    Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
    Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase.
    Watts PM; Riedl AG; Douek DC; Edwards RJ; Boobis AR; Jenner P; Marsden CD
    Neuroscience; 1998 Sep; 86(2):511-9. PubMed ID: 9881865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease.
    Shehadeh J; Double KL; Murphy KE; Bobrovskaya L; Reyes S; Dunkley PR; Halliday GM; Dickson PW
    Neurobiol Dis; 2019 Oct; 130():104524. PubMed ID: 31276794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.
    Ding YX; Xia Y; Jiao XY; Duan L; Yu J; Wang X; Chen LW
    Neurochem Res; 2011 Oct; 36(10):1759-66. PubMed ID: 21562748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
    Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Several neuropeptides involved in parkinsonian neuroprotection modulate the firing properties of nigral dopaminergic neurons.
    Chen L; Liu C; Xue Y; Chen XY
    Neuropeptides; 2023 Jun; 99():102337. PubMed ID: 37087783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Nogo-A-expressing neurons in a rat model of Parkinson's disease.
    Schawkat K; Di Santo S; Seiler S; Ducray AD; Widmer HR
    Neuroscience; 2015 Mar; 288():59-72. PubMed ID: 25554426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
    Swanson C; Emborg M
    Neurol Res; 2014 Jul; 36(7):634-46. PubMed ID: 24620964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
    Wang X; Yang HA; Wang XN; Du YF
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.